Molecular approach to targeted therapy for multiple sclerosis

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 1, 2016, Pages 20-34

  Sherbet, Gajanan V ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

Angiogenic growth factors; Chemokines; EBV; Immunomodulation; MicroRNAs; Molecular therapy; Multiple sclerosis; Signalling systems; Stem cells; Targeted therapy; Transcription factors; Vitamin D

Indexed keywords

ALEMTUZUMAB; CD40 ANTIGEN; CD40 LIGAND; COLECALCIFEROL; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; GLATIRAMER; IMMEDIATE EARLY PROTEIN BZLF1; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MITOXANTRONE; NATALIZUMAB; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OCRELIZUMAB; OFATUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RITUXIMAB; STAT PROTEIN; TERIFLUNOMIDE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN; AUTACOID; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ARTICLE; CLINICAL TRIAL (TOPIC); DEMYELINATION; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; MOLECULARLY TARGETED THERAPY; MULTIPLE SCLEROSIS; MYELINATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; IMMUNOLOGY; METABOLISM; PROCEDURES; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; MOLECULAR TARGETED THERAPY; MULTIPLE SCLEROSIS;

EID: 84958243961     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666151110125840     Document Type: Article

References (145)

1. Stathopoulos P, Alexopoulos H, Dalakas MC. Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nature Rev Neurol 2015; 11: 143-56.
2. Weissert R. The immune pathogenesis of multiple sclerosis. J Neuroimmune Pharmacol 2013; 8: 857-66.
3. Derfuss T, Parikh K, Velhin S, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci USA 2009; 106: 8302-7.
4. Boronat A, Sepulveda M, Llufriu S, et al. Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. J Neuroimmunol 2012; 244: 103-6.
5. Ji N, Somanaboneina A, Dixit A, et al. Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis. J Immnol 2013; 191: 5074-84.
6. Fridkis-Hareli M. Design of peptide immunotherapies for MHC Class-II-associated autoimmune disorders. Clin Develop Immunol 2013; 2013: 826191.
7. Clarke P, Leser JS, Bowen RA, Tyler KL. Virus-induced transcriptional changes in the brain include the differential expression of genes associated with interferon, apoptosis, interleukin 17 receptor A, and glutamate signaling as well as flavivirus-specific upregulation of tRNA synthetases. MBio 2014; 5(2): e00902-14.
8. Arbiser JL. Implications of Epstein-Barr virus (EBV)-induced carcinogenesis on cutaneous inflammation and carcinogenesis: Evidence of recurring patterns of angiogenesis and signal transduction. J Invest Dermatol 2005; 124: 11-12.
9. [9] Van Horssen J, Witte ME, Schreibeit G, De Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta Mo Basis of Dis 2011; 1812: 141-50.
10. McLean BN, Miller D, Thompson EJ. Oligoclonal banding of IgG in CSF, blood brain barrier function, and MRI findings in patients with scarcoidosis, systemic lupus erythymetosus and Behçet's disease involing the nervous system. J Neurol Neurosurg Psychiatry 1995; 58: 548-54.
11. Jefferis R, Lefrance MP. Human immunoglobulin allotypes. Possible implications for immunogenicity. Monoclonal Ab 2009; 1: 332-8.
12. Weng NP, Snyder JG, Yu-Lee LY, Marcus DM. Polymorphism of human immunoglobulin VH4 germ-line genes. Eur J Immunol 1992; 22: 1075-82.
13. Walter MA, Gibson WT, Eberes GC, Cox DW. Susceptibility to multiple sclerosis is associated with the proximal immunoglobulin heavy chain variable region. J Clin Invest 1991; 87: 1266-73.
14. Owens GP, Winges, KM, Ritchie AM, et al. V(H)4 gene segments dominate the intrathecal humoral immune response in multiple sclerosis. J Immunol 2007; 179: 6343-51.
15. Greer JM. Autoimmune T-Cell Reactivity to Myelin Proteolipids and Glycolipids in Multiple Sclerosis. MS Internat 2013; 2013: 151427.
16. Weber MS, Hemmer B and Cepok S. The role of antibodies in multiple sclerosis. Biochim Biophys Acta Mol Basis Dis 2011; 1912: 239-45.
17. Sherbet GV. Growth factors and their receptors in cell differentiation, cancer and cancer therapy, Elsevier; 2011.
18. Axelsson M, Mattsson N, Malmestrom C, Zetterberg H, Lycke J. The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis. J Neuroimmunol 2013; 264: 100-5.
19. Alvarez E, Piccio L, Mikesell RJ, et al. CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler 2013; 19: 1204-8.
20. Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflamm 2012; 9: 93.
21. Lourenco P, Shirani A, Saeedi J, Oger J, Schreiber WE, Tremlett H. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler J 2013; 19: 577-84.
22. Avasarala JR, Cross AH, Trotter JL. Oligoclonal band numbers as a marker for prognosis in multiple sclerosis. Arch Neurol 2001; 58: 2044-5.
23. Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol 2013; 262: 10.
24. Dobson R, Topping J, Davis A, Thompson E, Giovannoni G. Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurol Scand 2013; 128: 321-7.
25. Xu ZX, Wu J, Zheng JY, et al. Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors. Int Immunopharmacol 2015; 25: 528-537.
26. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232-41.
27. Al Fadhli S, Mohammed EMA, Al Shubaili A. Association analysis of nitric oxide synthases: NOS1, NOS2A and NOS3 genes, with multiple sclerosis. Ann Human Pathol 2013; 40: 368-75.
28. Gerritse K, Laman JD, Noelle RJ, et al. CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci USA 1996; 93 2499-504.
29. Elgueta R, Benson MJ, De Vries VC, Wasiukk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009; 229: 152-72.
30. Muerkoster S, Laman JD, Rocha M, Umansky V, Schirrmacher V. Functional and in situ evidence for nitric oxide production driven by CD40-CD40L interactions in graft-versus-leukemia reactivity. Clin Cancer Res 2000; 6: 1988-96.
31. Portillo JAC, Feliciano LM, Okenka G, Heinzel F.M, Subauste C, Subauste SC. CD40 and tumour necrosis factor-a co-operate to up- regulate inducible nitric oxide synthase expression in macrophages. Immunology 2011; 135: 140-50.
32. Holley JE, Newcombe J, Whatmore JL, Gutowski NJ. Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci Lett 2010; 47: 65-70.
33. Lengfeld J, Cutforth T, Agalliu D. The role of angiogenesis in the pathology of multiple sclerosis. Vasc cell 2014; 6: 23-9.
34. Girolamo F, Coppola C Ribatti D, Trojano M. Angiogenesis in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathol Commun 2014; 2: 84.
35. Seabrook TJ, Littlewood-Evans A, Brinkmann V, Pollinger B, Schnell C, Hiestand PC. Angiogenesis is present in experimental autoimmune encephalomyelitis and pro-angiogenic factors are increased in multiple sclerosis lesions. J Neuroinflamm 2010; 7.
36. Argaw AT, Asp L, Zhang J, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J Clin Invest 2012; 122: 2454-68.
37. Shaygannejad V, Montazeri S, Jamshidian A, et al. Correlation of midkine serum evel with pro- and anti-inflammatory cytokines in multiple sclerosis. Iran J Immunol 2014; 11: 134-8.
38. Pasquali L, Lucchesi C, Pecori C, et al. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis. J Neuroimmunol 2015; 278: 53-59.
39. Dobolyi A, Vincze C, Pal G, Lovas G. The neuroprotective functions of transforming growth factor beta proteins. Int J Mol Sci 2012; 13: 8219-58.
40. Iempridee T, Das S, Xu I, Mertz JE. Transforming growth factor β-induced reactivation of epstein-barr virus involves multiple smadbinding elements cooperatively activating expression of the latent- lytic switch BZLF1 gene. J Virol 2011; 85: 157836-48.
41. Kalla M, Schmeinck A, Bergbauer M, Pich D, Hammerschmidt W. P-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Aacd Sci USA 2010; 107: 850-5.
42. Bright JJ. Curcumin and autoimmune disease. Adv Exp Med Biol 2007; 595: 425-51.
43. Morrison TE Mauser A, Wong A, Ting JPY, Kenney SC. Inhibition of IFN-signaling by an Epstein-Barr virus immediate-early protein. Immunity 2001; 15: 787-99.
44. Morrison TE, Kenney SC. BZLF1, an Epstein-Barr virus immediate-early protein, induces p65 nuclear translocation while inhibiting p65 transcriptional function. Virology 2004; 328: 219-32.
45. Dreyfus DH, Liu Y, Ghoda LY, Chang JT. Analysis of an ankyrin-like region in Epstein Barr Virus encoded (EBV) BZLF-1 (ZEBRA) protein: implications for interactions with NF-κB and p53. Virol J 2011; 8: 422.
46. Benkhoucha M, Molnarfi N, Dunand-Sauthier I, et al. Hepatocyte growth factor limits autoimmune neuroinflammation via glucocorticoid-induced leucine zipper expression in dendritic cells. J Immunol 2014; 193: 2743-52.
47. Speck S, Lim J, Shelake S, et al. TGF-beta signaling initiated in dendritic cells instructs suppressive effects on Th17 differentiation at the site of neuroinflammation. PloS One 2014; 9: e102390.
48. Xue ZY, Ge ZZ, Zhang K, et al. Embelin suppresses dendritic cell functions and limits autoimmune encephalomyelitis through the TGF-beta/beta-catenin and STAT3 signaling pathways. Mol Neurobiol 2014; 49: 1087-101.
49. Huseby ES, Huseby PG, Shah S, Smith R, Stadinski BD. Pathogenic CD8 T Cells in multiple sclerosis and its experimental models. Front Immunol 2012; 3: 64.
50. Gupta S, Joshi K, Wig JD, Arora SK. Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncol 2007; 46: 792-7.
51. Cepok S, Marc Jacobsen M, Schlock S, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001; 124 2169-76.
52. Gopal AK, Press OW. Clinical applications of anti-CD20 CNPase is expressed in myelin-forming cells throughout their lineage. J Lab Clin Med 1999; 134: 445-50.
53. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 2012; 142: 31-7.
54. Meuth SG, Gobel K, Wiendl H. Immune therapy of multiple sclerosis - Future strategies. Curr Pharm Des 2012; 18: 4489-97.
55. Deiss A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother 2013; 13: 313-35.
56. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PloS One 2013; 8: e66308.
57. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with Rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67: 707-14.
58. Domagała A, Kurpisz M. CD52 antigen. A review. Med Sci Monitor 2001; 7: 325-31.
59. Rice GP, Haartung HP, Calabresi PA. Anti-alpha 4 integrin therapy for multiple sclerosis. Neurology 2005; 64: 1336-42.
60. Bielekova B. Daclizumab therapy for multiple sclerosis. Neurotherapeutics 2013; 10: 55-67.
61. Keiseier BC. The mechanism of action of interferon-β in relapsing multiple sclerosis. CNS Drugs 2011; 25: 491-502.
62. Gold R, Giovannoni G, Selmaj K, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 2013; 381: 2167-75.
63. Mi S, Miller RH, Lee X, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci 2005; 8: 745-51.
64. Mi S, Hu B, Hahm K, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med 2007; 13: 1228-33.
65. Mi S, Pepinsky RB, Cadavid D. Blocking LINGO-1 as a therapy to promote CNS repair: From concept to the clinic. CNS Drugs 2013; 27: 493-503.
66. Zhang YJ, Zhang YP, Pepinsky B, et al. Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination. Exptl Neurol 2015; 266: 68-73.
67. Ramgolam VS, Sha YG, Marcus KL, et al. B Cells as a therapeutic target for IFN-beta in relapsing-remitting multiple sclerosis. J Immunol 2011; 186: 4518-26.
68. Pflanz S, Timans JC, Cheung J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002; 16: 779-90.
69. Carl JW Jr, Bai XF. IL-27: Its role in the induction and inhibition of inflammation. Int J Clin Exp Pathol 2008; 1: 117-23.
70. Torre D, Gennero, L, Baccino FM, Speranza F, Biondi G, Pugliese A. Role of Th1 and Th2 cytokines in immune response to uncomplicated Plasmodium falciparum malaria. Clin Diag Lab Immunol 2002; 9: 348-51.
71. Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol 2010; 33: 91-101.
72. Fenoglio C, Ridolfi E, De Riz M, et al. Effect of fingolimod treatment on circulating miRNA levels in patients with multiple sclerosis. Mult Scler J 2013; 19: 544-5.
73. Durafourt B. Normalization of abnormal MicroRNA expression in monocytes of relapsing-remitting MS patients treated with fingolimod. 2014; onlinelibrary.ectrims-congress.eu/ectrims/2014/ACTRIMS.
74. Rossman IT, Cohen JA. Multiple sclerosis: Switching sidesfingolimod versus injectable MS therapies. Nat Rev Neurol 2015; 11(6): 316-7.
75. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 2014; 74: 659-74.
76. Cook MR, Pinchot SN, Kunnimalaiyaan M, Chen H. Teriflunomide activates the Notch pathway and leads to carcinoid cancer growth suppression by cell cycle arrest. J Am Coll Surg 2009; 209: S34.
77. Cook MR, Pinchot SN, Jaskula-Sztul R, Luo J, Kunnimalaiyaan M, Chen H. Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth. Mol Cancer Ther 2010; 9: 429-37.
78. Huang O, Zhang W, Zhi Q, et al. Teriflunomide, an immuno-modulatory drug, exerts anticancer activity in triple negative breast cancer cells. Exp Biol Med 2015; 240: 426-37.
79. Balague C, Pont M, Prats N, Godessart N. Profiling of dihydroo-rotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant- induced arthritis model: a translational study. Br J Pharmacol 2012; 166: 1320-32.
80. Huang GH, Wang YY, Vogel P, Chi HB. Control of IL-17 receptor signaling and tissue inflammation by the p38 alpha-MKP-1 signaling axis in a mouse model of multiple sclerosis. Sci Signal 2015; 8: ra24.
81. Sherbet GV. Therapeutic strategies in cancer biology and pathology. Elsevier 2013.
82. Gill AJ, Kolson DL. Dimethyl fumarate modulation of immune and antioxidant Responses: Application to HIV therapy. Crit Rev Immunol 2013; 33: 307-59.
83. Wiesner D, Merdian I, Lewerenz J, Ludolph AC, Dupuis L, Witting A. Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1 alpha and Nrf2. PloS One 2013; 8: e76670.2.
84. Tsubaki M, Ogawa N, Takeda T, et al. Dimethyl fumarate induces apoptosis of hematopoietic tumor cells via inhibition of NF-kappa B nuclear translocation and down-regulation of Bcl-xL and XIAP. Biomed Pharcother 2014; 68: 999-1005.
85. Peng HY, Guerau-de-Arellano M, Mehta VB, et al. Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kappa B (NF-kappa B) and extracellular signal-regulated kinase 1 and 2 (ERK1/2) and mitogen stress-activated kinase 1 (MSK1) signalling. J Biol Chem 2012; 287: 28017-26.
86. Kansanen E, Kuosmanen SM, Leinonen H, Levonen AL. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol 2013; 1: 45-9.
87. Parodi B, Rossi S, Morando S, et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS. Acta Neuropathol 2015; 130: 279-95.
88. Uccelli A, Moretta L, Pistoria V. AImmunoregulatory function of mesenchymal stem cells. Eur J Immunol 2006; 36: 2566-73.
89. Uccelli A, Laroni A, Freedman MS. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011; 10: 649-56.
90. Rice CM, Kemp K, Wilkins A, Scolding NJ. Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet 2013; 382: 1204-13.
91. Radaelli M, Merlini A, Greco R, et al. Autologous bone marrow transplantation for the treatment of multiple sclerosis. Curr Neurol Neurosc Rep 2014; 14: 478.
92. de Paula ASA, Malmegrim KCR, Panepucci RA, et al. Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis. Clin Sci 2015; 128: 111-20.
93. Harris TJ, Grosso JF, Yen HR, et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17- dependent autoimmunity. J Immunol 2007; 179: 4313-7.
94. Yu CR, Lee YS, Mahdi RM, Surendran N, Egwuagu CE. Therapeutic targeting of STAT3 (Signal Transducers and Activators of Transcription 3) pathway inhibits experimental autoimmune uveitis. PloS One 2012; 7: e29742.
95. Holloman JP, Ho CC, Hukki A, Huntley JL, Gallicano GI. The development of hematopoietic and mesenchymal stem cell transplantation as an effective treatment for multiple sclerosis. Am J Stem Cells 2013; 2: 95-107.
96. Patil A, Sherbet GV. Therapeutic approach to the management of HER2-positive breast cancer metastatic to the brain. Cancer Lett 2015; 358: 93-9.
97. Frank RT, Edmiston M, Kendall SE, et al. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. Plos One 2009; 4: e8314.
98. Doze A, Perez DM. GPCRs in stem cell function. Prog Mol Tranl Sci 2015; 115: 175-219.
99. Potocnik AJ, Brakebusch C, Fässler R. Fetal and adult hematopoietic stem cells require beta1 integrin function for colonizing fetal liver, spleen, and bone marrow. Immunity 2000; 12: 653-63.
100. Qian H, Tryggvason K, Jacobsen SE, Ekblom M. Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins. Blood 2006; 107: 3503-10.
101. Michailidou I, de Vries HE, Hol EM, van Strien ME. Activation of endogenous neural stem cells for multiple sclerosis therapy. Front Neurosci 2014; 8: 454.
102. Li ZC, Li K, Zhu L, et al. Inhibitory effect of IL-17 on neural stem cell proliferation and neural cell differentiation. BMC Immunol 2013; 14: 20.
103. Yang JX, Jiang Z, Fitzgerald DC, et al. Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelination in experimental autoimmune encephalitis. J Clin Invest 2009; 119: 3678-91.
104. Yang JX, Yan YP, Xia Y, et al. Neurotrophin 3 transduction augments remyelinating and immunomodulatory capacity of neural stem cells. Mol Ther 2014; 22: 440-50.
105. Khezri S, Javan M, Goudarzvand M, Semnanian S, Baharvand H. Dibutyryl cyclic AMP inhibits the progression of experimental autoimmune encephalomyelitis and potentiates recruitment of endogenous neural stem cells. J Mol Neurosci 2013; 51: 298-306.
106. Wen DZ, Peles E, Cupples R, et al. Neu differentiation factor. A transmembrane glycoprotein containing an EGF domain and an immunoblobulin homology unit. Cell 1992; 69: 559-72.
107. Mei L, Nave KA. Neuregulin-erBB signaling in the nervous system and neuropsychiatric diseases. Neuron 2014; 83: 27-49.
108. Taveggia C, Feltri ML, Wrabetz L. Signals to promote myelin formation and repair. Nature Rev Neurol 2010; 6: 276-87.
109. Dai JX, Bercury KK, Macklin WB. Interaction of mTOR and Erk1/2 signaling to regulate oligodendrocyte differentiation. Glia 2014; 62: 2096-109.
110. Sachs HH, Bercury KK, Popescu DC, Narayanan SP, Macklin WB. A new model of cuprizone-mediated demyelination/remyelination. ASN Neuro 2014; 6: 1759091414551955.
111. Kumar S, Patel R, Moore S, et al. Estrogen receptor beta ligand therapy activates PI3K/Akt/mTOR signaling in oligodendrocytes and promotes remyelination in a mouse model of multiple sclerosis. Neurobiol Dis 2013; 56: 131-44.
112. Harrington EP, Zhao CO, Fancy SPJ, Kaing S, Franklin RJM, Rowitch, DH. Oligodendrocyte PTEN is required for myelin and axonal integrity, not remyelination. Ann Neurol 2010; 68: 703-16.
113. Noseda R, Belin S, Piguet F, et al. DDIT4/REDD1/RTP801 is anovel negative regulator of Schwann cell myelination. J. Neurosci 2013; 33: 15295-305.
114. Blank T, Prinz M. NF-κB signalling regulates myelination in the CNS. Frontiers Mol Neurosci 2014; 7: 47.
115. Vento-Tormo R, Rodriguez-Ubreva J, Di Lisio L, et al. NF-kappa B directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B- cells and in lymphomas. Nucleic Acids Res 2014; 42: 11025-39.
116. Dzeng RK Jha HC, Lu J, Saha A Banerjee S, Robertson ES. Small molecule growth inhibitors of human oncogenic gammaherpesvirus infected B-cells. Mol Oncol 2015; 9: 365-76.
117. Hoffmann G, Schobersberger W. Neopterin: a mediator of the cellular immune system. Pteridines 2004; 15: 107-12.
118. Cepok S, Zhou D, Srivastava R, et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest 2005; 115: 1352-60.
119. Serafini B, Rosicarelli B, Franciotta D, Magiozzi R, Reyolds R, Cinque P. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204: 2899-912.
120. Pender MP, Burrows SR. Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clin Transl Immunol 2014; 3: e27.
121. Miller WE, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF- kappaB activation. J Virol 1997; 71: 586-94.
122. Edwards RH, Marquitz AR, Raab-Traub N. Epstein-Barr virus BART microRNAs are produced from a large intron prior to splicing. J Virol 2008; 82: 9094-106.
123. Klinke O, Feederle R, Delecluse HJ. Genetics of Epstein-Barr virus microRNAs. Semin Cancer Biol 2014; 26: 52-9.
124. Kanda T, Miyata M, Kano M, Kondo S, Yoshizaki T, Iizasa H. Clustered microRNAs of the Epstein-Barr virus cooperatively downregulate an epithelial cell-specific metastasis suppressor. J Virol 2015; 89: 2684-97.
125. Ma X, Zhou J, Zhong Y, et al. Expression, regulation and function of microRNAs in multiple sclerosis. Int J Med Sci 2014; 11: 810-8.
126. Qu Z, Li W, Fu B. MicroRNAs in autoimmune diseases. BioMed Res Int 2014; 2014: 527895.
127. Mansouri S, Pan Q, Blencowe BJ, Claycomb JM, Frappier L. Epstein-Barr virus EBNA1 protein regulates viral latency through effects on let-7 microRNA and dicer. J Virol 2014; 88: 11166-77.
128. Cox JE, McClure LV, Goga A, Sullivan CS. Pan-viral-microRNA screening identifies interferon inhibition as a common function of diverse viruses. Proc Natl Acad Sci USA 2015; 112: 1856-61.
129. Ingwersen J, Menge T, Wingerath B, et al. Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b. Ann Clin Trans Neurol 2015; 2: 43-55.
130. He Z, Jiang J, Kokkinaki M, et al. MiRNA-20 and mirna-106a regulate spermatogonial stem cell renewal at the post-transcriptional level via targeting STAT3 and Ccnd1. Stem Cells 2013; 31: 2205-17.
131. Gu F, Hata R, Ma YJ, et al. Suppression of Stat3 promotes neurogenesis in cultured neural stem cells. J Neurosci Res 2005; 81: 163-71.
132. Jackson D. Alpha 4 integrin antagonists. Curr Pham Des 2002; 8: 1229-53.
133. Kamphuis WW, Derada TC, Reijerkerk A, Romero IA, De Vries HE. The blood-brain barrier in multiple sclerosis: microRNAs as key regulators. CNS Neurol Disor Drug Targets 2015; 14: 157-67.
134. Wagner KD, Wagner N, Sukhatme VP, Scholz H. Activation of vitamin D receptor by the Wilms' tumor gene product mediates apoptosis of renal cells. J Am Soc Nephrol 2001; 12; 1188-96.
135. Lin R, Taylor BV, Charlesworth J, et al. Modulating effects of WT1 on interferon-beta-vitamin D association in MS. Acta Neurol Scand 2015; 131: 231-9.
136. Helming L, Bose J, Ehrchen J, et al. 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005; 106: 4351-8.
137. Huang JK, Ferrari CC, Monteiro de Castro G, et al. Accelerated axonal loss following acute CNS demyelination in mice lacking protein tyrosine phosphatase receptor type. Z Am J Pathol 2012; 181: 1518-23.
138. Shirazi HA, Rasouli J, Ciric B, Rostami A, Zhang GX. 1,25(OH)2D3 has a direct effect on NSC proliferation, survival, and neuron/oligodendrocyte differentiation, thus representing a novel mechanism underlying its remyelinating and neuroprotective effect in MS/EAE therapy. Exp Mol Pathol 2015; 98: 240-5.
139. Chang SH, Chung Y, Dong C. Vitamin D suppresses Th17 cytokine production by inducing C/EBP homologous protein (CHOP) expression. J Biol Chem 2010; 285: 38751-5.
140. Aivo J, Hanninen A, Ilonen J, Soilu-Hanninen M. Vitamin D3 administration to MS patients leads to increased serum levels of latency activated peptide (LAP) of TGF-beta. J Neuroimmunol 2015; 280: 12-5.
141. Glenn TD, Talbot WS. Analysis of Gpr126 function defines distinct mechanisms controlling the initiation and maturation of myelin. Development 2013; 140: 3167-75.
142. Gonzalez-Pardo V, D'Elia N, Verstuyf A, Boland R, de Boland AR. NF kappa B pathway is down-regulated by 1 alpha,25(OH)(2)- vitamin D-3 in endothelial cells transformed by Kaposi sarcoma- associated herpes virus G protein coupled receptor. Steroids 2012; 77: 1025-32.
143. Subramanian S, Miller LM, Grafe MR, Vandenbark AA, Offner, H. Contribution of GPR30 for 1,25 dihydroxyvitamin D-3 protection in EAE. Metabol Brain Dis 2012; 27: 29-35.
144. Cui HX, Wang YQ, Huang HZ, et al. GPR126 protein regulates developmental and pathological angiogenesis through modulation of VEGFR2 receptor signaling. J Biol Chem 2014; 289: 34871-85.
145. Hennen S, Wang HB, Peters L, et al. Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal 2013; 6: ra93.